1. In Vivo

Spotting Zebras: Technology Cutting Through The Diagnostic Odyssey

 
• By Jo Shorthouse

In Vivo talked to two organizations making progress in the diagnosis of rare diseases using software and genomic sequencing.

Zebra
• Source: Shutterstock

“When you hear hoofbeats, think horses not zebras,” is a saying well known to young doctors to remind them to think of the most common and likely diagnosis when assessing a patient. However, if a clinician is not that familiar with rare conditions, they may struggle to treat the horse when they should have diagnosed a zebra all along.

It is thought that around 350 million people are affected by undiagnosed genetic diseases, outnumbering people living with cancer and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Akelos’ Peripheral HCN1 Blocker Looks To End Opioid Dependence In Neuropathic Pain

 
• By Jo Shorthouse

Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.